StockData
GRI Bio, Inc. logo

GRI Bio, Inc. (GRI) stock

GRINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.27−0.08 (-5.95%)

Close on Nov 18, 2026Market cap $2.78MP/E –Yield –

GRI Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

GRI Bio's operating income for the twelve months ending Jun 30, 2026 was -$9.68M. For fiscal 2025 it was -$11.98M. The highest annual figure on record is -$2.24M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$11.98M–
FY2024Dec 31, 2024-$8.24M–
FY2023Dec 31, 2023-$11.39M–
FY2022Dec 31, 2022-$2.24M–
FY2021Dec 31, 2021-$9.26M–
FY2020Dec 31, 2020-$4.79M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.65M–
Q1 FY2026Mar 31, 2026-$2.00M–
Q4 FY2025Dec 31, 2025-$2.66M–
Q3 FY2025Sep 30, 2025-$3.37M–
Q2 FY2025Jun 30, 2025-$2.90M–
Q1 FY2025Mar 31, 2025-$3.05M–
Q4 FY2024Dec 31, 2024-$1.95M–
Q3 FY2024Sep 30, 2024-$2.13M–
Q2 FY2024Jun 30, 2024-$2.26M–
Q1 FY2024Mar 31, 2024-$1.90M–
Q4 FY2023Dec 31, 2023-$2.03M–
Q3 FY2023Sep 30, 2023-$2.44M–
Q2 FY2023Jun 30, 2023-$5.93M–
Q1 FY2023Mar 31, 2023-$988.00K–
Q4 FY2022Dec 31, 2022-$1.67M–
Q3 FY2022Sep 30, 2022-$186.00K–
Q2 FY2022Jun 30, 2022-$189.00K–
Q1 FY2022Mar 31, 2022-$2.63M–
Q4 FY2021Dec 31, 2021-$3.09M–
Q3 FY2021Sep 30, 2021-$1.25M–
Q2 FY2021Jun 30, 2021-$2.31M–
Q1 FY2021Mar 31, 2021-$2.60M–
Q4 FY2020Dec 31, 2020-$1.46M–
Q3 FY2020Sep 30, 2020-$1.03M–
Q2 FY2020Jun 30, 2020-$1.14M–
Q1 FY2020Mar 31, 2020-$1.16M–

More GRI Bio figures

See a number that looks wrong?